Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind randomized trial
| Autor: | Jane Percy, William T. McGaw, Michael Grace, Sheri M. Samuels, G. Wayne Raborn |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male medicine.medical_specialty Randomization medicine.medical_treatment Acyclovir Dosage form Pathology and Forensic Medicine law.invention Ointments Random Allocation Randomized controlled trial Double-Blind Method law Recurrence Medicine Humans Aciclovir skin and connective tissue diseases General Dentistry Herpes Labialis Chemotherapy business.industry virus diseases Dermatology Clinical trial Aqueous cream Anesthesia Female business medicine.drug |
| Zdroj: | Oral surgery, oral medicine, and oral pathology. 67(6) |
| ISSN: | 0030-4220 |
| Popis: | The efficacy of 5% acyclovir in a modified aqueous cream vehicle (ACV-MAC) in the treatment of recurrent herpes labialis was tested in a randomized, double-blind clinical trial with the modified aqueous cream vehicle as a control medication. The ACV-MAC formulation has previously been shown to offer superior cutaneous absorption relative to other topical acyclovir formulations. Treatment was initiated by patients within 1 hour of prodrome in an attempt to maximize clinical impact of this virustatic drug. While the patient group receiving active drug showed a trend toward accelerated healing, no significant differences for lesion or healing characteristics could be measured between the two treatment groups. It is suggested that optimal efficacy of ACV-MAC may be predicated on prophylactic treatment, that is, "trigger"-initiated rather than prodrome-initiated treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|